Taihua plc, an investment holding company, develops, manufactures, distributes, and sells traditional Chinese medicine TCM products and active pharmaceutical ingredients APIs in China. The company operates in four segments: Paclitaxel, Homoharringtonine, TCM Products, and Forsythia. Its APIs products include paclitaxel, which is extracted from the bark of the yew tree for the treatment of ovaries, breast, lungs, skin, and mucous membranes cancer; and Homoharringtonine, an alkaloid extracted from branches and leaves of the cephalotaxus tree for the treatment of acute myeloid leukaemia and other cancers. The company also offers TCM products, including gengnianan tablet, duzhong pingya tablet, zaoren anshen keli, bunao anshen tablet, jiangzi jianfei tablet, dabaidu capsule, runing tablet, and bian tong pian. In addition, it cultivates, harvests, and sells Forsythia, a flowering shrub for use as the basis of TCM preparations. The company was formerly known as China Natural Plc and changed its name to Taihua plc in September 2006. Taihua plc was incorporated in 2006 and is based in Xi'an, China.